KR20240006026A - 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 - Google Patents

주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 Download PDF

Info

Publication number
KR20240006026A
KR20240006026A KR1020237040558A KR20237040558A KR20240006026A KR 20240006026 A KR20240006026 A KR 20240006026A KR 1020237040558 A KR1020237040558 A KR 1020237040558A KR 20237040558 A KR20237040558 A KR 20237040558A KR 20240006026 A KR20240006026 A KR 20240006026A
Authority
KR
South Korea
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
anxiety
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237040558A
Other languages
English (en)
Korean (ko)
Inventor
로베르트 알폰소 라세르
제임스 도허티
제프리 마틴 조나스
스티븐 제이 케인스
한단 군두즈-브루스
헬렌 앤 콜크혼
라이언 아놀드
비자이비르 본타팔리
조이 리사 던바
뱀뱅 세노아지 아디위자야
Original Assignee
세이지 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세이지 테라퓨틱스, 인크. filed Critical 세이지 테라퓨틱스, 인크.
Publication of KR20240006026A publication Critical patent/KR20240006026A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237040558A 2021-04-29 2022-04-29 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 Pending KR20240006026A (ko)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US63/181,743 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US63/197,025 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US63/210,810 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US63/239,096 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US63/285,812 2021-12-03
US202163289506P 2021-12-14 2021-12-14
US202163289520P 2021-12-14 2021-12-14
US63/289,506 2021-12-14
US63/289,520 2021-12-14
US202263298601P 2022-01-11 2022-01-11
US63/298,601 2022-01-11
PCT/US2022/026920 WO2022232504A1 (en) 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Publications (1)

Publication Number Publication Date
KR20240006026A true KR20240006026A (ko) 2024-01-12

Family

ID=81748925

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237040558A Pending KR20240006026A (ko) 2021-04-29 2022-04-29 주요 우울 장애 및 산후 우울증을 치료하는 데 사용하기 위한 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드

Country Status (11)

Country Link
US (1) US20240216395A1 (cg-RX-API-DMAC7.html)
EP (2) EP4768044A2 (cg-RX-API-DMAC7.html)
JP (2) JP2024515829A (cg-RX-API-DMAC7.html)
KR (1) KR20240006026A (cg-RX-API-DMAC7.html)
AU (1) AU2022266680A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022264A2 (cg-RX-API-DMAC7.html)
CA (1) CA3218072A1 (cg-RX-API-DMAC7.html)
IL (1) IL307991A (cg-RX-API-DMAC7.html)
MX (1) MX2023012727A (cg-RX-API-DMAC7.html)
TW (1) TW202308654A (cg-RX-API-DMAC7.html)
WO (1) WO2022232504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ,インコーポレイテッド うつ病の治療方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2025508406A (ja) * 2022-02-16 2025-03-26 セージ セラピューティクス, インコーポレイテッド Cns関連障害を処置するための神経活性ステロイド

Also Published As

Publication number Publication date
EP4329770A1 (en) 2024-03-06
CA3218072A1 (en) 2022-11-03
US20240216395A1 (en) 2024-07-04
WO2022232504A1 (en) 2022-11-03
JP2024515829A (ja) 2024-04-10
JP2025111701A (ja) 2025-07-30
TW202308654A (zh) 2023-03-01
MX2023012727A (es) 2023-11-08
IL307991A (en) 2023-12-01
EP4768044A2 (en) 2026-07-01
AU2022266680A1 (en) 2023-11-02
BR112023022264A2 (pt) 2024-01-23

Similar Documents

Publication Publication Date Title
US20250339447A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
TW202539683A (zh) 透過投予(r)-2[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)吡唑並[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧雜環丁烷-3-基)哌𠯤-1-基]戊-2-烯腈治療中度至重度氣喘
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
RU2851101C2 (ru) 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения
EP4673123A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000